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Identification of 6-amino-1H-pyrazoloĳ3,4-
d]pyrimidines with in vivo efficacy against visceral
leishmaniasis†
Michael G. Thomas, a Manu De Rycker, a Myriam Ajakane,b Sabrinia D. Crouch,c
Lorna Campbell,a Alain Daugan,b Gloria Fra,d César Guerrero,d Claire J. Mackenzie,a
Lorna MacLean,a Sujatha Manthri,a Franck Martin,b Suzanne Norval,a
Maria Osuna-Cabello,a Jennifer Riley,a Yoko Shishikura,a Juan Miguel-Siles,c
Frederick R. C. Simeons,a Laste Stojanovski,a John Thomas,a Stephen Thompson,a
Raul F. Velasco,d Jose M. Fiandor,c Paul G. Wyatt,a Kevin D. Read,a
Ian H. Gilbert*a and Timothy J. Miles *c
Visceral leishmaniasis (VL) affects millions of people across the world, largely in developing nations. It is
fatal if left untreated and the current treatments are inadequate. As such, there is an urgent need for new,
improved medicines. In this paper, we describe the identification of a 6-amino-N-(piperidin-4-yl)-1H-
pyrazoloĳ3,4-d]pyrimidine scaffold and its optimization to give compounds which showed efficacy when
orally dosed in a mouse model of VL.
Introduction
Visceral leishmaniasis (VL) is caused by infection with the
protozoan parasites L. donovani and L. infantum and is
typically fatal unless treated, infecting around 50000–90 000
people annually and resulting in a death toll of between
20000–30 000.1,2 Current therapies suffer from numerous
issues such as high cost, problematic modes of dosing, and
toxicity.3 In addition, the global development pipeline for VL
is sparse with four additional new chemical entities (NCEs)
just entering the early pre-clinical phase.4–7 There is therefore
an urgent need for new therapeutic classes to help tackle this
neglected disease.
The primary objective of this program was therefore to
identify safe, effective, oral, short-course (ideally ≤10 days)
drug candidates for VL, in line with the DNDi (Drugs for
Neglected Disease initiative) target product profile.8 Due to a
lack of validated druggable targets for VL, we focused on
chemical series that showed antiparasitic activity in an assay
involving parasites growing in mammalian cells, aiming to
progress these into in vivo efficacy studies, where they could
be bench-marked against miltefosine; this currently being
the only available oral therapy for VL. This phenotypic
approach was used successfully for the identification of two
preclinical candidates.5,7 One of these, DDD853651/
GSK3186899 was developed from pyrazolopyrimidine 1, with
a key step being elaboration of the cyclohexylamine to a
sulfonamide substituted 1,4-trans-cyclohexyldiamine (Fig. 1).
In this work, we describe further modifications to the
cyclohexylamine, leading to a series of substituted
4-aminopiperidines which displayed efficacy in a mouse
model of VL.
Results and discussion
For the identification of DDD853651/GSK3186899, which
contained a trans-1,4-cyclohexyldiamine, a key strategy was to
optimise the balance between potency in the intracellular
Leishmania assay (L. donovani in THP-1 cells, referred to as
Ld InMac assay9) and solubility.10 In that case, we focused on
2 (Table 1), where the sulfonamide was required for potency
but was poorly soluble. We noted that amide 3, whilst
inactive, did show improved aqueous solubility (51 vs. 1 μM),
so we investigated alternative central units to identify start
points which retained activity and showed improved
solubility compared to 2. To this end, we examined a
4-aminopiperidine central unit with both sulfonamide and
amide substituents (Table 1). In contrast to the trans-1,4-
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cyclohexyldiamine series, the equivalent sulfonamide was
>10-fold less active (5 cf. 2), whilst amide 4 was >10-fold
more active than its comparator (4 cf. 3) and showed similar
aqueous solubility (59 μM cf. 51 μM). We therefore selected 4
as a suitable start-point for further chemistry. As previously
discussed,10 in order to progress to in vivo studies we
targeted compounds with pEC50 > 5.8, solubility > 100 μM
and intrinsic clearance (Cli) < 5.0 ml min
−1 g−1 (mouse liver
microsomes), so we explored the SAR around 4, initially
focusing on the amide substituent. We noted that either
lengthening the linker to the aromatic ring, or removing it,
led to a loss of activity (6 and 7 respectively). Substitution of
the phenylacetamide led to 2,4-difluorinated analogue 8 with
an increase in potency compared to 4, whilst other changes,
such as the dichloro analogue 9 and α-methyl analogue 10
failed to improve potency, although 10 did show improved
aqueous solubility, possibly due to the introduction of a sp3
centre.
Fig. 1 Initial active compound 1 and preclinical candidate DDD853651/GSK3186899.
Table 1 SAR of analogues with iso-butyl LHS
R Compound Ld InMaca pEC50 THP-1
a pEC50
Aqueous
solubilityb μM
Cli mouse
c
ml min−1 g−1
2 6.2 <4.3 <1 27
3 <4.3 <4.3 51 NDd
4 5.1 <4.3 59 18
5 4.9 <4.3 10 >50
6 4.7 <4.3 NDd NDd
7 <4.3 <4.3 291 7
8 5.8 <4.3 26 12
9 5.0 <4.3 26 30
10 (rac) 5.3 <4.3 140 NDd
a Ld InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes.9 Data are the mean values for n ≥ 3 replicates
and standard deviations are ≤0.3. b Aq. solubility is kinetic aqueous solubility (CAD).11 c Cli is mouse liver microsomal intrinsic clearance.10
d ND means not determined.
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With 2,4-difluorophenylacetamide 8 as the most potent
RHS (right hand side, see Fig. 1 in the introduction)
identified, we explored the SAR (structure activity
relationship) around the LHS (left hand side, see Fig. 1 in the
Introduction) to improve solubility and metabolic stability,
initially focusing on alkyl substituents (Table 2). Neopentyl
11 was inactive whilst the smaller cyclopropyl group of 12
maintained potency and displayed improved metabolic
stability. Changing the cyclopropyl group for tetrahydropyran
(THP) led to 13, with a pEC50 value of 6.0, a small
improvement in solubility, and excellent metabolic stability.
To further improve the physicochemical characteristics of the
series, we examined the methylene-linked morpholine 14
which also showed excellent metabolic stability, although it
was only weakly active. Removing the methylene linker gave
the directly attached morpholine 15, which retained in vitro
potency and metabolic stability, whilst switching to O-linked
compound 16 gave a drop in activity.
To further explore the SAR around 13, with a cyclic
substituent on the LHS, a series of aromatic groups were
explored. Phenyl substituted 17 showed an increase in
potency compared to 9, although it was hampered by poor
solubility; this was improved slightly by moving to the more
polar pyridyl analogue 18, and moving to 5-membered
heteroaromatics such as 19 also improved metabolic stability,
albeit with a 10-fold loss in potency. A variety of other 5 and
6-membered heteroaromatics were explored, but none led to
significant improvements (data not shown). Substitution on
the aromatic ring of 17 was also investigated, leading to the
2-methoxyphenyl analogue 20, with a pEC50 value of 7.1 in
the Ld InMac assay. This was one of the most potent
analogues in the series, comparing very favourably with the
standard treatments for VL, amphotericin B and miltefosine
(pEC50's of 6.7 and 6.1 respectively). In an attempt to further
improve solubility, methoxypyridyl analogue 21 was
synthesized; whilst potency of 20 was maintained and
solubility was improved, poorer microsomal stability was
observed.
Having demonstrated that variations to the RHS (Table 1)
and LHS (Table 2) could deliver compounds with a good
balance of potency, solubility and metabolic stability, we
switched our attention to the core pyrazolopyrimidine and the
central unit (Table 3). Although we later elucidated the target of
the series as being Leishmania-CRK12 (cyclin related kinase
Table 2 SAR of analogues with N-(2,4-difluorophenylacetyl)piperidine RHS
R Compound Ld InMac pEC50
a THP-1a pEC50
Aqueous
solubilityb μM
Cli mouse,
c
ml min−1 g−1
11 <4.3 <4.3 27 22.0
12 5.9 <4.3 39 5.0
13 6.0 <4.3 78 0.5
14 4.6 <4.3 NDd <0.5
15 6.1 <4.3 14 2
16 5.2 <4.3 33 NDd
17 6.5 <4.3 <1 7.2
18 6.1 <4.3 23 6.7
19 5.5 4.7 30 3.3
20 7.1 4.4 <1 5.0
21 7.1 <4.3 25 15
a Ld InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes.9 Data are the mean values for n ≥ 3 replicates
and standard deviations are ≤0.4. b Aq. solubility is kinetic aqueous solubility (CAD).11 c Cli is mouse liver microsomal intrinsic clearance.10
d ND means not determined.
RSC Medicinal Chemistry Research Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
A
ug
us
t 2
02
0.
 D
ow
nl
oa
de
d 
on
 8
/1
8/
20
20
 1
2:
16
:3
5 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
RSC Med. Chem. This journal is © The Royal Society of Chemistry 2020
Table 3 SAR around the core and central unit
Compound Comparator Ld InMac pEC50
a THP-1 pEC50
a
22 9 <4.3 <4.3
23 20 4.7 <4.3
24 9 <4.3 <4.3
25 9 <4.3 <4.3
26 20 <4.3 <4.3
27 20 5.2 5.0
28 20 5.2 <4.3
29 (S) 18 4.9 <4.3
30 (R) 18 <4.3 <4.3
31 (cis) 20 4.5 4.6
32 (trans) 20 4.8 4.5
33 20 5.4 4.4
34 18 <4.3 <4.3
35 20 <4.3 <4.3
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12),5 at this point we were reliant on phenotypic drug discovery
strategies to drive compound design. We were aware that
intermolecular hydrogen bonding between the donor–acceptor
pairs within the core was likely to be detrimental to solubility
(Fig. 2), as was the planarity of the compounds.10 We therefore
synthesized a set of analogues to probe the SAR around the
various hydrogen bond donor–acceptor pairs in the core, and
also examined a further series of central units to identify any
that could maintain potency whilst adding more flexibility and
three-dimensional character.
Alkylation of the aminopyrimidine N–H or replacement by
oxygen to give 22 and 23 respectively, led to a >10-fold
reduction in potency compared to its' matched molecular
pair (compounds 9, 18 and 20 were all used as comparators
for this exercise). Additionally, alkylation of the pyrazole N–H
(24) as well as replacement of the pyrazole with isoxazole (25)
or pyrrole (26) all led to a >10-fold loss of potency. The
pyrazole ring was opened to give pyridimines 27 and 28,
leading to decreased potency and also toxicity against the
host THP-1 cells in the case of 27.
Switching attention to the central unit, 3-aminopiperidine
enantiomers 29 and 30 and the 1,3-diaminocyclohexyl
analogues 31 and 32 were either weakly active or inactive, as
was methylated aminopiperidine 33. More flexible linkers
such as aminomethylpiperidine 34, aminomethylcyclobutyl
35 and ethylenediamine 36 were also inactive. Further diverse
linkers, with numerous substituents (amides and
sulfonamides) were tested, but all proved to be inactive
beyond the already identified piperidines and 1,4-trans-
cyclohexylamines (data not shown).
Refocusing on 20, where the introduction of the
2-methoxyphenyl LHS gave a significant improvement in
potency, further RHS piperidine substituents were explored
(Table 4). Introduction of the trifluoropropylsulfonamide
from the preclinical candidate (DDD853651/GSK3186899) did
give a potent compound (37) although with very poor
solubility and intrinsic clearance; this was similar for
carbamate linked compounds 38 and 39. Conversely, urea
linked compounds such as 40 maintained reasonable
solubility and metabolic stability but reduced potency. Also,
directly attaching a heterocycle led to 41 with very good
potency but low solubility. Finally we examined a further set
of amides, identifying cyclopropylmethyl analogue 42 with
good potency and metabolic stability, and 3,4-difluorophenyl
analogue 43 with improved potency and solubility compared
to 20.
Utilising the SAR understanding we had developed, a set
of analogues were synthesized that combined the most
interesting LHS and RHS (Table 5). Maintaining the
cyclopropylmethyl amide of 42 led to the THP (44), 2-pyridyl
(45) and morpholine (46) analogues that were only
moderately potent but were much more soluble, with 44 also
having very good metabolic stability. Maintaining the 3,4-
difluorophenyl RHS led to THP 47 and morpholine 48, both
of which had reasonable potency, high solubility and good
metabolic stability. Finally, the chloropyridazine RHS led to
THP analogue 49 which was reasonably potent and
morpholine 50 which again showed good potency, solubility
and metabolic stability.
To select the most suitable compounds to progress to
in vivo studies, the fasted state simulated intestinal fluid
(FaSSIF) solubility of 20, 42, 48 and 50 was measured,13 as
this had proved to be successful for triaging compounds in
the 1,4-trans-cyclohexyldiamine series.10 20, the most potent
compound with Cli ≤ 5.0 ml min−1 g−1, and 42, which had
moderate aqueous solubility, both had FaSSIF solubility of
<1 μg ml−1, whereas 48 and 50 had FaSSIF solubilities of 97
and 88 μg ml−1 respectively. On this basis, 48 and 50 were
progressed into orally dosed pharmacokinetic studies in
female Balb-c mice (Table 6), with both having sufficient Cmax
(the highest concentration of a drug in the blood) and AUC
(area under the curve) to progress into the previously
reported mouse efficacy model of VL.10
Both compounds were dosed orally for 5 days (Table 7),
with 48 giving 60% reduction of parasite liver load at the
lower dose, and 98% reduction at the higher dose, and 50
giving 17% reduction at the lower dose and 57% at the
higher dose. For 48, this met our criteria for progression
Table 3 (continued)
Compound Comparator Ld InMac pEC50
a THP-1 pEC50
a
36 18 <4.3 <4.3
a Ld InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes.9 Data are the mean values for n ≥ 3 replicates
and standard deviations are ≤0.3.
Fig. 2 Hydrogen bond donor–acceptor pairs in 8.
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Table 4 SAR of analogues with 2-methoxyphenyl LHS
R Compound Ld InMac pEC50
a THP-1 pEC50
a Aqueous solubilityb μM Cli mouse,
c ml min−1 g−1
20 7.1 4.4 <1 5.0
37 6.7 <4.3 <1 14
38 6.3 4.4 24 14
39 6.4 <4.3 NDd 9
40 5.7 <4.3 79 2
41 6.8 <4.3 412 3.4
42 6.5 4.4 22 1.6
43 7.6 4.8 53 6.3
a Ld InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes.9 Data are the mean values for n ≥ 3 replicates
and standard deviations are ≤0.4. b Aq. solubility is kinetic aqueous solubility (CAD).11 c Cli is mouse liver microsomal intrinsic clearance.10
d ND means not determined.
Table 5 Designed analogues based on key SAR
R1 R2 Compound Ld InMac pEC50
a THP-1 pEC50
a Aqueous solubilityb μM Cli mouse
c ml min−1 g−1
44 5.1 <4.3 ≥496 0.8
45 5.3 <4.3 ≥392 NDd
46 4.8 <4.3 NDd NDd
47 6.0 <4.3 ≥429 3.1
48 6.1 <4.3 ≥465 1.6
49 5.8 <4.3 6312 NDd
50 6.2 <4.3 12112 0.6
a Ld InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes.9 Data are the mean values for n ≥ 3 replicates
and standard deviations are ≤0.4. b Aq. solubility is kinetic aqueous solubility (CAD).11 c Cli is mouse liver microsomal intrinsic clearance.10
d ND means not determined.
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towards candidate selection and it was therefore profiled
more fully.
At this point, the target of the series was demonstrated to
be the parasitic kinase Leishmania-CRK12, so to fully
understand kinase selectivity 48 was further profiled against
a panel of 140 human kinase receptors at 10 μM
concentration.14 From this, only 4 kinases were inhibited at
>40% (ERK8 [extracellular signal-regulated kinases], p38α
and p38β MAPK [mitogen-activated protein kinases] and
CDK2 [cyclin dependant kinase]). Full IC50 curves were
generated for these, showing that the kinases most affected
were ERK8 (IC50 = 0.11 μM) and p38β MAPK (IC50 = 0.55 μM).
We didn't consider these results to preclude further
development of 48.
A further in vivo study demonstrated that 48 had a mean
liver : blood ratio of 4.8 : 1 which could prove beneficial, as
the liver is one of the major sites of parasitic burden in VL
infections.2 48 was also progressed to a rat dose-escalation
study in order to determine whether exposures higher than
the efficacious exposure could be achieved (Table 8); this
would be critical in order to progress the compound to rat
toxicology studies. In this case, increasing the dose from 100
to 300 mg kg−1 led to only a 1.2-fold increase in Cmax and a
1.7-fold increase in AUC(0-Tlast) suggesting that it would be
challenging to determine a therapeutic index in future
toxicological studies.
In order to synthesise the compounds described, a
number of different synthetic routes were utilized, as
outlined in Schemes 1–4. Scheme 1 shows the synthetic route
that was used to access compounds 4–10, where the readily
accessible 2-chloro-4-methoxy pyrimidine 5110 was treated
with the Boc (tert-butyloxycarbonyl protecting group)
protected aminopyrimidine 52 to give 53, which was
deprotected under acidic conditions to give 54. This was
subsequently coupled with a relevant acid then cyclized with
hydrazine to yield analogues 4–7 and 9–10. Alternately, an
elaborated aminopiperidine could be coupled with 51 to give
55a (R = benzylsulfonyl) or 55b (R = 2,4-difluorobenzoyl)
which were cyclized to give compounds 5 and 8 respectively.
Compounds 11–21, with the 2,4-difluorophenacetamide
RHS and variations to the LHS were synthesized according to
Scheme 2, such that 56, with an appropriate R-group (R1 =
a–d in table), was coupled to 52 and the resulting
intermediate Boc-deprotected by treatment with TFA to give
57a–d. 57a and 57b were coupled to 2,4-difluorophenylacetic
acid and subsequently cyclized with hydrazine to give 11 and
12. Compounds 40, 42, 43 and 47 were synthesized by a
similar procedure using 57c or d and a suitable acid.
Alternately, 56d–g were coupled directly with the elaborated
aminopiperidine 58 to give 59d–g and cyclized with hydrazine
to give compounds 13 and 18–21. 14 was synthesized by a
similar route, but after 59i was cyclised to give 60,
deprotection of the intermediate TBDMS alcohol gave 61
which was mesylated and displaced with morpholine. Finally,
by choosing suitably substituted aminopiperidines alongside
the relevant 56, intermediates 62c–e were generated and
cyclized to give compounds 37–39, 41, 44, 45 and 49.
Scheme 3 highlights the synthetic routes to compounds
with variations to the linking group between the pyrimidine
core and the RHS amide (22–36). For compounds 22, 23 and
29–36, a suitably substituted 2-chloro-4-methoxy pyrimidine
(51 or 56c, e) was treated with the relevant mono-Boc
protected diamine 63a–j. These were subsequently
deprotected and coupled with 2,4-difluorophenylacetic acid to
give 64a–j which were cyclized with hydrazine to give the
relevant compound. Alternatively, treatment of 64k with
ammonia gave the monocyclic analogue 27. For compounds
24 and 25, 65 was generated from 56a and 58 then cyclized
with either methylhydrazine or hydroxylamine to give 24 and
25 respectively. Replacement of the pyrazolopyrimidine
scaffold with a 7H-pyrroloĳ2,3-d]pyrimidine required a
separate synthesis, whereby Boc protected 66 was cross-
coupled with 2-methoxyphenylboronic acid and subsequently
Boc-reprotected to give 67 which was coupled with 58 and
then Boc deprotected to give 26.
Finally, the 3-morpholinopyrazole analogues 15, 46, 48 and
50 were synthesized via cyclisation of relevant thioamides as
Table 6 Pharmacokinetic profile of compounds 48 and 50 in Balb-c
mice, dosed orally
Compound
Dose
mg kg−1
AUC ng
min ml−1
Cmax
ng ml−1 Tmax h
48 100 1 253 767 5765 1
50 100 2 388 964 5229 4
Vehicle was 0.5% weight/volume (w/v) hydroxypropylmethylcellulose
with 0.4% volume/volume (v/v) Tween 80 and 0.5% v/v benzyl
alcohol. Tmax is the time where the highest concentration of drug in
the blood is achieved.
Table 7 Mouse efficacy model of VL for 48 and 50
Compound Dosing regimen
% Suppression
of parasite load
48 30 mg kg−1 b.i.d. for 5 days PO 60
48 100 mg kg−1 b.i.d. for 5 days PO 98
50 25 mg kg−1 b.i.d. for 5 days PO 17
50 50 mg kg−1 b.i.d. for 5 days PO 57
Vehicle was 0.5% w/v hydroxypropylmethylcellulose with 0.4% v/v
Tween 80 and 0.5% v/v benzyl alcohol. b.i.d. means twice (bis in die)
a day. PO (Per Os) means oral administration.
Table 8 Rat PK data for 48 at 10, 100 and 300 mg kg−1
Dose (mg kg−1) Cmax (ng ml
−1) Tmax (h)
AUC (0-Tlast)
(ng h ml−1)
10 229 0.67 488
100 5520 6.00 50621
300 6760 6.67 84647
Vehicle was 0.5% w/v hydroxypropylmethylcellulose.
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previously described,10 and shown in Scheme 4. 68 was
therefore treated with 52 to give 69. Treatment with
Lawessons reagent led to thioamide 70 which was cyclized
with hydrazine to give 71, with subsequent Boc deprotection
yielding 72. This was coupled with the relevant acid to give
15, 46 and 48, or treated with 3,6-dichloropyridazine to give
50.
In summary, an aminopiperidine subseries of the
previously disclosed pyrazolopyrimidines was identified as
having potent in vitro antileishmanial activity. SAR
exploration demonstrated that the core and central unit were
optimal for activity, whilst optimization of the RHS and LHS
led to 48, with in vivo efficacy suitable for progression
towards preclinical candidate selection. Whilst further
profiling of 48 showed that it had a good safety profile, with
only relatively weak inhibition of four human kinases
highlighted, a dose escalation study in rats showed that 48
had infra-linear increase in exposure; this, alongside a
Scheme 1 Synthesis of compounds 4–10. (a) N,N-Diisopropylethylamine (DIPEA), butan-1-ol; (b) trifluoroacetic acid (TFA), dichloromethane
(DCM), 97% (over 2 steps); (c) R–COOH, N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU), DIPEA, DCM; (d) hydrazine
hydrate, butan-1-ol, 30–56% (over 2 steps).
Scheme 2 Synthesis of compounds 11–21, 37–45, 47 and 49. (a) DIPEA, butan-1-ol; (b) TFA, DCM, 47–83% (over 2 steps); (c) R2–COOH, TBTU,
DIPEA, dimethylformamide (DMF); (d) hydrazine hydrate, butan-1-ol, 22–48% (over 2 steps); (e) tetra-n-butylammonium fluoride (TBAF), THF, 86%;
(f) methanesulfonyl chloride (MsCl), DIPEA, acetonitrile (MeCN) then morpholine, 18%.
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minimum efficacious dose of 100 mg kg−1 meant that the
compound was not progressed further. Despite this, the
aminopiperidine subseries demonstrated the potential to
deliver an alternative Leishmania CRK12 inhibitor for the
treatment of VL.
Ethical statements
Mouse and rat pharmacokinetics
All animal studies were ethically reviewed and carried out in
accordance with Animals (Scientific Procedures) Act 1986 and
Scheme 3 Synthesis of compounds 22, 23, 26, 29–36. (a) (i) DIPEA, butan-1-ol (ii) TFA, DCM (iii) TBTU, DIPEA, DCM; (b) hydrazine hydrate, butan-
1-ol, 14–43% (over steps a and b); (c) ammonium hydroxide, ethanol (EtOH), 83%; (d) DIPEA, butan-1-ol; (e) (i) methylhydrazine, DIPEA, butan-1-ol
(for 24), 18% (over 2 steps) (ii) hydroxylamine. Hydrogen chloride (HCl), DIPEA, butan-1-ol (for 25), 10% (over 2 steps); (f) (i)
(2-methoxyphenyl)boronic acid, potassium phosphate (K3PO4), bisĲdi-tert-butylĲ4-dimethylaminophenyl)phosphine)dichloropalladiumĲII), MeCN (ii)
Boc2O, sodium hydride (NaH), THF, 92%; (g) DIPEA, N-methyl-2-pyrrolidone (NMP), 17%.
Scheme 4 Synthesis of 15, 46, 48 and 50. (a) 1-Boc-4-aminopiperidine, DIPEA, butan-1-ol, 67%; (b) Lawessons reagent, THF, 86%; (c) hydrazine
hydrate, 1,4-dioxane, 94% (d) TFA/DCM, 100% (e) (i) R–COOH, TBTU, DIPEA, DMF (for 15, 46 and 48) (ii) 3,6-dichloropyridazine, DIPEA, EtOH (for
50), 36–43%.
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the GlaxoSmithKline (GSK)/Dundee University policies on the
care, welfare, and treatment of animals.
In vivo efficacy
All regulated procedures, at the University of Dundee, on
living animals were carried out under the authority of a
project license issued by the Home Office under the Animals
(Scientific Procedures) Act 1986, as amended in 2012 (and in
compliance with EU Directive EU/2010/63). License
applications will have been approved by the University's
Ethical Review Committee (ERC) before submission to the
Home Office. The ERC has a general remit to develop and
oversee policy on all aspects of the use of animals on
University premises and is a subcommittee of the University
Court, its highest governing body.
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